Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, recently attended and presented at the Cellular Therapies and Transfusion Medicine in Trauma and Critical Care conference.  The CTTACC conference took place on December 11-13, 2019 in San Diego, California.  The meeting brought together clinicians, scientists, academics, and representatives from various health organizations with a goal to discuss the science and barriers surrounding the use of cellular therapies in trauma and critical care.

PSC Co-Founder and Chief Scientific Officer, Dr. Bob Harman

PSC Chief Scientific Officer, Dr. Robert Harman, was asked to participate as a panelist in a session entitled Optimizing Cell Product Development and Delivery to Patients.  According to Dr. Harman, “Trauma creates a major need for stem cells.”  Since stem cells have been shown to act immediately to reduce cell death, modulate inflammation, block pain, and reduce fibrosis, it is clear there is a place for cell therapy in trauma and critical care medicine.

In July of 2019, PSC received FDA approval for a New Drug (IND) application to conduct clinical trials for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical trial for the treatment of knee osteoarthritis was launched in September 2019 and is ongoing.

This is the first of several planned clinical trials which will enable qualified PSC-enrolled physicians to provide FDA compliant, quality cell therapy to patients suffering from osteoarthritis. PSC plans to conduct a series of FDA approved clinical trials starting with uses in orthopedics and expanding to other medical conditions such as trauma in the future.